Survival and prognostic factors in patients with epithelial ovarian cancer receiving paclitaxel and carboplatin as first-line chemotherapy in Japanese women: A multi-center retrospective study

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 15022-15022
Author(s):  
H. Kajiyama ◽  
F. Kikkawa ◽  
M. Kawai ◽  
K. Mizuno ◽  
I. Kobayashi ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Prognostic Factors ◽  
Retrospective Study ◽  
Epithelial Ovarian Cancer ◽  
Clear Cell ◽  
Histological Grade ◽  
Clinical Stage ◽  
Progression Free Survival ◽  
Figo Stage ◽  
Second Line

15022 Background: The aim of this retrospective study was to re-evaluate, multi-analytically, survival and prognostic factors of patients with epithelial ovarian cancer (EOC) receiving the combination of paclitaxel and carboplatin (PC). Methods: Between 1/00 and 12/04, a total of 335 cases with EOC of FIGO stage I-IV are registered in a multi-institutional series. All patients received cytoreductive surgery and combination chemotherapy of paclitaxel 180 mg/m2/3 hr and carboplatiion AUC = 5 for a total of 6 cycles. We retrospectively analyzed progression-free survival (PFS) and overall survival (OS) of these patients by stratification of assumable several prognostic factors and second-line regimen. Survival probabilities were estimated by Kaplan-Meier methods, and prognostic factors for survival were evaluated by a COX proportional hazard model. Results: Median age was 54 ± 11 years (range 9–81). The 3-, 4- and 5-year OS in patients was 67.0%, 53.9% and 50.6%, respectively. In a COX analysis, FIGO stage, histological type and residual tumor (2 cm < vs. 2 cm >; P = 0.0007, HR; 2.4, 95% CI = 1.4–4.0) were found to be independent significant factors for OS. The stratification analysis revealed that stage III-IV patients with clear cell and mucinous carcinoma have poorer prognosis than those with other histological types ( Table ). In contrast, no differences in histological grade (G1 vs. G2; P = 0.82, HR; 0.9, 95% CI = 0.5–1.6, G1 vs. G3; P = 0.65, HR; 0.9, 95% CI = 0.4–1.6) and kinds of second-line regimen were noticed for PFS and OS. Conclusions: Optimal surgical debulking, clinical stage, and histology appear to be important prognostic factors of survival in patients with EOC. This retrospective study suggests that PC may still have an impact on outcome. However, further strategy will be needed for improving survival of mucinous and clear-cell type EOC, especially with advanced stage. [Table: see text] No significant financial relationships to disclose.

scholarly journals Evaluation of the relationship between CD163 positive macrophages and prognostic factors in serous ovarian tumors

2020 ◽  
Vol 6 (2) ◽  
pp. e23-e23
Author(s):  
Mitra Heidarpour ◽  
Marjan-Sadat Hoseini-Beheshti ◽  
Maryam Derakhshan
Keyword(s):  
Ovarian Cancer ◽  
Prognostic Factors ◽  
Survival Rate ◽  
Histological Grade ◽  
Clinical Stage ◽  
Figo Stage ◽  
Ovarian Tumors ◽  
Cross Sectional ◽  
Tissue Samples ◽  
Gynecology And Obstetrics

Introduction: Ovarian cancer is the seventh most common cancer in women and is the fifth most common cause of mortality from malignancy. Objectives: The present study was performed to evaluate the number of CD163 positive macrophages and prognostic factors in serous ovarian tumors. Materials and Methods: In the present cross-sectional study, 43 tissue samples obtained from patients with serous ovarian tumors were selected from the pathology ward of Al-Zahra hospital, Isfahan, Iran. Then, the patients’ demographic information including age, pathological results, clinical stage of the disease, degree of tissue differentiation, the number of CD163 positive macrophages, and the five-year survival rate after the surgery were recorded and evaluated. Results: Patient age, International Federation of Gynecology and Obstetrics (FIGO) stage, histological grade, lymphatic metastasis, and the five-year survival rate were positively and significantly associated with the number of CD163 positive macrophages (P <0.05). In addition, the number of CD163 positive macrophages increased the odds of the five-year survival rate in these patients by 1.490 times (P = 0.026). Conclusion: According to the results of this study, the number of CD163 positive macrophages had a significant association with the progression of ovarian cancer. Moreover, the increased number of CD163 positive macrophages increased the chance of mortality in these patients.

scholarly journals Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols

2019 ◽  
Vol 69 (1) ◽  
pp. 87-97
Author(s):  
Saima Sattar ◽  
Mobasher Ahmad ◽  
Hamid Saeed ◽  
Zikria Saleem ◽  
Zeeshan Danish ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Histological Grade ◽  
Progression Free Survival ◽  
Complete Response ◽  
Recurrent Ovarian Cancer ◽  
Figo Stage ◽  
Care Hospital ◽  
Pathological Characteristics ◽  
Literature Evidence

Abstract Despite growing prevalence of ovarian cancer (OC) in Pakistan, no literature evidence exists regarding its clinic-pathological characteristics, survival and compliance of patients with recurrent ovarian cancer on various chemo-protocols. An observational study was conducted by enrolling 251 recurrent OC patients on 7 different chemo-protocols, from a specialized cancer care hospital, Lahore, Pakistan, using convenient judgmental sampling. The study was conducted for a period of 6 months. Most of the patients were between 18 and 70 years of age, with IIIC FIGO stage and papillary serous histological grade. As per RECIST, improved partial response (PR) (63.3 %) and complete response (CR) (52.1 %) was observed in the CP (carboplatin + paclitaxel) arm, substantiated by improved median progression free survival (PFS) and overall survival (OS) in CP and CD (carboplatin + docetaxel) arms, respectively, yet with no significant differences in survival curves, PFS (p = 0.12) and OS (p = 0.22). Interestingly, the highest and the lowest patient non-compliance were observed in CG (carboplatin + gemcitabine) (81.6 %) and paclitaxel (4.5 %) arms, resp. As per the hazard model for survival, topotecan showed significant association with the therapy related events/deaths compared to other protocols. These data suggest that CP regimen exhibited improved clinical efficacy and decreased toxicity related non-compliance in recurrent ovarian cancer patients of Lahore.

Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer

2016 ◽  
Vol 26 (4) ◽  
pp. 626-631 ◽  
Author(s):  
Michelle M. Boisen ◽  
Jamie L. Lesnock ◽  
Scott D. Richard ◽  
Sushil Beriwal ◽  
Joseph L. Kelley ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Gynecologic Oncology ◽  
Progression Free Survival ◽  
Primary Response ◽  
Published Data ◽  
Second Line ◽  
First Recurrence ◽  
Oncology Practice ◽  
Platinum Chemotherapy

ObjectiveOnly 3% of patients with epithelial ovarian cancer (EOC) have a longer treatment-free interval (TFI) after second-line intravenous (IV) platinum chemotherapy than with frontline IV therapy. We sought to examine what impact second-line combination IV/intraperitoneal (IV/IP) platinum therapy might have on the ratio of second-line to first-line TFI in patients treated with second-line IP platinum chemotherapy for first recurrence after front-line IV therapy.MethodsA retrospective analysis of women who received combination platinum-based IV/IP chemotherapy for recurrent EOC between January 2005 and March 2011 was conducted. Patients were identified from the tumor registry, and office records from a large gynecologic oncology practice and patient records were reviewed. The first and second TFIs were defined as the time from the end of previous platinum-based therapy to the start of next therapy.ResultsTwenty-five women received IV/IP chemotherapy for their first EOC recurrence after IV chemotherapy. In 10 patients (40%), we observed a longer TFI after IV/IP chemotherapy than after primary IV chemotherapy. For these 10 patients, the median TFI for primary response was 22 months (range, 15–28), whereas median TFI after IV/IP chemotherapy for recurrent disease was 37 months (range, 12–61).ConclusionsFor EOC patients with limited peritoneal recurrence, 40% of patients had a second-line IP-platinum TFI that exceeded their frontline IV-platinum TFI compared to published data. These data support the use of IV/IP chemotherapy as a treatment for recurrence.

An evaluation of survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: A Gynecologic Oncology Group experience.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 5534-5534 ◽  
Author(s):  
John H. Farley ◽  
William E. Brady ◽  
Michael J. Birrer ◽  
David Marc Gershenson ◽  
Gini F. Fleming ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Prognostic Factors ◽  
Epithelial Ovarian Cancer ◽  
Cell Carcinoma ◽  
Treatment Effect ◽  
Late Stage ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Early Stage ◽  
Performance Status

5534 Background: We examined disparities in prognosis between patients with ovarian clear cell carcinoma (OCCC) and serous epithelial ovarian cancer (SOC). Methods: Data from stage I-IV epithelial ovarian cancer (EOC) patients who participated in 12 randomized GOG protocols using platinum-based chemotherapy were reviewed. Proportional hazards models adjusted for age and stratified by protocol, treatment arm, stage, performance status (PS), and race were used to compare progression-free survival (PFS) and overall survival (OS) by cell type (clear cell versus serous). Results: There were 10,803 patients enrolled, 1272 were not eligible: leaving 9,531, of whom 544 (6%) had OCCC, 7,054 (74%) had SOC, and 1,933 (20%) had other; only the OCCC and SOC are considered here. OCCC were significantly younger, more often of Asian race, stage I, good PS, and optimally surgically debulked than SOC patients. Prior to adjustment, OCCC had better PFS and OS due to better prognostic factors. There was no significant difference in PFS or OS for early stage OCCC patients compared to high-grade (HG) SOC patients. For late stage patients, OCCC had poorer PFS and OS compared to SOC, OS HR= 1.66 (1.43, 1.91; p < 0.001). For both optimal, HR = 1.34 (1.10, 1.63; p = 0.003) and suboptimal, HR = 3.18 (2.13, 4.75; p < 0.001) OCCC had a significantly poorer OS than SOC. After adjusting for age and stratified by protocol and treatment arm, stage, performance status, and race, OCCC had a significantly decreased OS, HR= 1.53 (1.33,1.76; p < 0.001). In early stage cases, there was a significantly decreased treatment effect on PFS for consolidative therapy with weekly taxol versus observation in SOC compared to OCCC (p = 0.048). Conclusions: This is one of the largest analyses to date of OCCC treated in a uniform manner . OCCC patients have better PFS and OS compared to SOC; this, is due to their better prognostic factors. There was no observed difference in PFS or OS for early stage OCCC versus HGSOC. In late-stage patients, OCCC was significantly associated with decreased OS which was true for both optimal and suboptimally debulked patients. Finally, treatment effect was influenced by histology.

DEMOGRAPHIC PROFILE AND OUTCOMES OF ADVANCED EPITHELIAL OVARIAN CANCER

2021 ◽  
Vol 5 (5) ◽  
Author(s):  
Ankit Agarwal ◽  
Arun Pandey ◽  
Giriraj Prajapati
Keyword(s):  
Ovarian Cancer ◽  
Prognostic Factors ◽  
Epithelial Ovarian Cancer ◽  
Clinical Stage ◽  
Tertiary Care ◽  
Survival Rates ◽  
Disease Free Survival ◽  
Abdominal Distension ◽  
Care Hospital ◽  
Loss Of Appetite

Background: To study the epidemiological features and outcome of epithelial ovarian cancer patients treated at a tertiary care hospital. Methods: We conducted a retrospective study at our institute to identify patients diagnosed with epithelial Ovarian Carcinoma (EOC) from 2013 to 2018. We studied the epidemiological profile and the outcome of the treatment in terms of response rates, Disease-free survival, and overall survival rates. Results: A total of 238 patients were diagnosed with EOC over a period of 7 years. Out of 238 patients, complete pretreatment data was available for 197 patients. The median age at diagnosis was 59 years (range: 34–85 years). Totally 39 patients (16.38%) were younger than 45 years of age. The common presenting features were abdominal distension (82%), dysuria (43%), abdominal pain (40%), loss of appetite (36%), constipation (32%), shortness of breath (15%). serum CA125 levels were elevated in 73% cases at presentation Conclusion: In conclusion, it is of extreme importance to identify the prognostic factors in patients with ovarian cancer to enable us to choose the most appropriate treatment strategy and to identify the risk of progression and death at follow-up. In our study, the patient age and FIGO clinical stage were the only independent prognostic factors reported. Keywords: FIGO, Ovarian, Germ cell

Prognostic Factors of Stage IV Epithelial Ovarian Cancer: A Multicenter Retrospective Study

2001 ◽  
Vol 81 (3) ◽  
pp. 398-403 ◽  
Author(s):  
Jun-Ichi Akahira ◽  
Hiroyuki Yoshikawa ◽  
Yoshio Shimizu ◽  
Ryuichiro Tsunematsu ◽  
Toshio Hirakawa ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Prognostic Factors ◽  
Retrospective Study ◽  
Epithelial Ovarian Cancer ◽  
Stage Iv
Sign in / Sign up

Export Citation Format

Share Document